Milestone Pharmaceuticals
MIST
39 hedge funds and large institutions have $60.7M invested in Milestone Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 11 closing their positions.
107% more call options, than puts
Call options by funds: $601K | Put options by funds: $290K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% more capital invested
Capital invested by funds: $59M → $60.7M (+$1.71M)
3.38% less ownership
Funds ownership: 62.01% → 58.63% (-3.4%)
19% less funds holding
Funds holding: 48 → 39 (-9)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFA
Alta Fundamental Advisers
New York
|
+$865K |
| 2 |
BlackRock
New York
|
+$403K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$109K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$19.2K |
| 5 |
Goldman Sachs
New York
|
+$10.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$663K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$539K |
| 4 |
Barclays
London,
United Kingdom
|
-$483K |
| 5 |
Morgan Stanley
New York
|
-$325K |
MIST Hedge Fund Activity: Q3 2023 in Review
39 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2023, worth a combined $60.7M — up 2.9% from $59M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MIST and 2 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was Alta Fundamental Advisers, adding an estimated $865K. The largest seller was Boxer Capital, cutting an estimated $1.21M.
- 39 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2023, down from 48 in Q2 2023.
- Funds reported $60.7M of Milestone Pharmaceuticals stock for Q3 2023, up 2.9% quarter-over-quarter.
- 2 funds opened new Milestone Pharmaceuticals positions in Q3 2023 and 11 closed out, a net change of -9 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2023 was Alta Fundamental Advisers, an estimated $865K added.
- The largest Milestone Pharmaceuticals seller in Q3 2023 was Boxer Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2023.